BRAINLIFE Brain Tumor Medical Database

Chemoresistance

Home > Database > Treatment > Chemoresistance

Contents



Anaplastic Astrocytomas


Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B.
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma
Eur J Cancer. 2008 Oct 20; [Epub ahead of print]
  Abstract


Cancer Research


Dolan ME, Pegg AE
O6-benzylguanine and its role in chemotherapy
Clin Cancer Res 1997 Jun;3(6):837-47

Pegg AE
Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents
Cancer Res 1990 Oct 1;50(19):6119-29

Pourquier P, Waltman JL, Urasaki Y, Loktionova NA, Pegg AE, Nitiss JL, Pommier Y
Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine
Cancer Res 2001 Jan 1;61(1):53-8
(PDF Full Text)


Choroid Plexus Tumors


Hasselblatt M, Mühlisch J, Wrede B, Kallinger B, Jeibmann A, Peters O, Kutluk T, Wolff JE, Paulus W, Frühwald MC
Aberrant MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation in choroid plexus tumors
J Neurooncol. 2009 Jan;91(2):151-5. Epub 2008 Sep 16
  Abstract


Glioblastoma


Balana C, Ramirez JL, Taron M, Roussos Y, Ariza A, Ballester R, Sarries C, Mendez P, Sanchez JJ, Rosell R
O(6)-methyl-guanine-DNA methyltransferase Methylation in Serum and Tumor DNA Predicts Response to 1,3-Bis(2-Chloroethyl)-1-Nitrosourea but not to Temozolamide Plus Cisplatin in Glioblastoma Multiforme
Clin Cancer Res 2003 Apr;9(4):1461-8 

Benyahia B, Huguet S, Decleves X, Mokhtari K, Criniere E, Bernaudin JF, Scherrmann JM, Delattre JY
Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1
J Neurooncol. 2004 Jan;66(1-2):65-70. (Abstract+)

Lorena Bissola, Marica Eoli, Francesca Menghi, Bianca Pollo, Antonio Silvani, Giovanni Broggi, Amerigo Boiardi, Gaetano Finocchiaro
MGMT promoter hypermethylation is more frequent in secondary glioblastomas and is independent from other prognostic factors
Proceedings of the AACR, Volume 45, March 2004. Abstract Number: 1077 

Bleau AM, Huse JT, Holland EC
The ABCG2 resistance network of glioblastoma
Cell Cycle. 2009 Sep 15;8(18):2936-44
  Abstract

Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M
O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
Neuro Oncol. 2010 Mar;12(3):283-8
  Abstract

Alba Ariela Brandes, Mario Ermani, Umberto Basso, Lara Maria Pasetto, Francesca Vastola, Franco Berti, Silvia Berlucchi, Pietro Amistà, Antonello Rotilio, Silvio Monfardini
Procarbazine Prior to and Concomitant with BCNU in Patients with Glioblastoma at First Relapse: a Phase II Study
ASCO Proceedings, 2001 Annual Meeting, Abstract 


Carlson CNO, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):212-9
  Abstract

Costa BM, Caeiro C, Guimarães I, Martinho O, Jaraquemada T, Augusto I, Castro L, Osório L, Linhares P, Honavar M, Resende M, Braga F, Silva A, Pardal F, Amorim J, Nabiço R, Almeida R, Alegria C, Pires M, Pinheiro C, Carvalho E, Lopes JM, Costa P, Damasceno M, Reis RM.
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study
Oncol Rep. 2010 Jun;23(6):1655-62
  Abstract

Della Puppa A, Persano L, Masi G, Rampazzo E, Sinigaglia A, Pistollato F, Denaro L, Barzon L, Palù G, Basso G, Scienza R, d'Avella D.
MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?
J Neurooncol. 2011 Jul 2. [Epub ahead of print]
  Abstract |   Related articles

Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
Br J Cancer. 2009 Jul 7;101(1):124-31. Epub 2009 Jun 16
  Abstract

Durmaz R, Deliorman S, Uyar R, Isiksoy S, Erol K, Tel E
The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme
Clin Neurol Neurosurg. 1999 Dec;101(4):238-44
 

Franceschi E, Tosoni A, Pozzati E, Brandes AA
Association between response to primary treatments and MGMT status in glioblastoma
Expert Rev Anticancer Ther. 2008 Nov;8(11):1781-6
  Abstract

Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN, Tang JB, Sobol RW.
Overcoming Temozolomide Resistance in Glioblastoma via Dual Inhibition of NAD+ Biosynthesis and Base Excision Repair.
Cancer Res. 2011 Mar 15;71(6):2308-17.
  Abstract |   Related articles

Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
J Clin Oncol. 2008 Sep 1;26(25):4189-99
 Abstract

Kitange GJ, Carlson CNO, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, David James C, Sarkaria JN
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model
J Neurooncol. 2008 Nov 15. [Epub ahead of print]
  Abstract

Kitange GJ, Carlson CNO, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Neuro Oncol. 2008 Nov 3; [Epub ahead of print] First published on October 24, 2008
  Abstract

Koch D, Hundsberger T, Boor S, Kaina B.
Local intracerebral administration of O6-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma
J Neurooncol. 2006 Sep 20; [Epub ahead of print]
Abstract

Li S, Zhang W, Chen B, Jiang T, Wang Z
Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy
Neurol Res. 2009 Aug 21. [Epub ahead of print]
  Abstract

Löw S, Vougioukas VI, Hielscher T, Schmidt U, Unterberg A, Halatsch ME
Pathogenetic pathways leading to glioblastoma multiforme: association between gene expressions and resistance to erlotinib
Anticancer Res. 2008 Nov-Dec;28(6A):3729-32
  Abstract

Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, Bigner DD, Friedman HS.
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma
Clin Cancer Res. 2008 Aug 1;14(15):4859-68
 Abstract

Mellai M, Caldera V, Annovazzi L, Chiò A, Lanotte M, Cassoni P, Finocchiaro G, Schiffer D
MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas
Cancer Genomics Proteomics. 2009 Jul-Aug;6(4):219-27
  Abstract

Park CK, Park SH, Lee SH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW
Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin
Neuropathology. 2009 Jan 6. [Epub ahead of print]
  Abstract |   Full Text |   Reprint

Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG, McDonald KL.
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
J Neurooncol. 2007 Nov 15; [Epub ahead of print]
Abstract

Preusser M, Janzer RC, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M
Anti-O6-Methylguanine-Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker
Brain Pathol. 2008 Apr 8;. [Epub ahead of print]
  Abstract

Meg Verrees, Lili Liu, Stanton L. Gerson
Interruption of base excision repair selectively enhances temozolamide and 1,3-bis(2-chloroethyl)-nitrosurea cytotoxicity in treatment of adult human malignant glioma cell lines
Proceedings of the AACR, Volume 45, March 2004, Abstract Number: 1548. 

Watson AJ, Sabharwal A, Thorncroft M, McGown G, Kerr R, Bojanic S, Soonawalla Z, King A, Miller A, Waller S, Leung H, Margison GP, Middleton MR
Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib
Clin Cancer Res. 2010 Jan 15;16(2):743-9. Epub 2010 Jan 12
  Abstract

Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME.
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Nat Rev Neurol. 2009 Dec 8;. [Epub ahead of print]
  Abstract

Elderly patients


Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F
Correlation between O(6)-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide
J Neurooncol. 2010 Aug 5. [Epub ahead of print]
  Abstract


Gliomas


Beith J., Cook R., Robinson B., Levi J., Bell D., Wheeler H. 
Modulation of resistance to BCNU by depleting MGMT activity with procarbazine in patients with relapsed high-grade gliomas

ASCO Proceedings, 1997 Annual Meeting, Abstract No. 1375 

Dora B. Bocangel, Sydney Finkelstein, S. Clifford Schold, Kishor K. Bhakat, Sankar Mitra and Demetrius M. Kokkinakis
Multifaceted Resistance of Gliomas to Temozolomide
Clinical Cancer Research Vol. 8, 2725-2734, 1 August 2002
 Abstract |  Full Text |  Reprint

T. Burton, P. Baijal, E. Henson, S. Zhang, S.B. Gibson, and D.D. Eisenstat
The Hypoxia-Inducible Cell Death Gene BNIP3 In Malignant Gliomas
Society for Neuro-Oncology Eighth Annual Meeting. Keystone, Colorado. November 13–16, 2003. Abstract No. AN-05.
Neuro-Oncology, Volume 5, CNO 4, October 2003 

S. M. Chang, W. K. A. Yung, J. Kuhn, D. Schiff, H. Fine, M. Mehta, I. Robins, L. Junck, K. Hess, M. Prados
Phase II study of neoadjuvant BCNU and temozolomide for newly diagnosed anaplastic glioma
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 413 

Francis Ali-Osman, Olanike Akande, Gamil Antoun, and Henry Friedman
Transcriptional activitation of the GSTP1 gene by wind-type p53 results in a DNA-mismatch-repair–dependent NER: a novel p53-GSTP1 mediated mechanism of alkylator resistance in human gliomas
15th International Conference on Brain Tumor Research and Therapy. Sorrento, Italy. May 24–27, 2003. Abstract No. 2 
Neuro-Oncology, Volume 5, CNO 4, October 2003 

Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME
O6-benzylguanine-mediated enhancement of chemotherapy
Mol Cancer Ther 2002 Sep;1(11):943-8
Henry S Friedman, James Pluda, Jon Weingart, Henry Brem, Brandon Evans, William Petros, Jeremy Rich, Sandra Tourt-Uhlig, Sridharan Gururangan, David Reardon, John Sampson, Allan Friedman, James Provenzale, Roger McLendon, O. M Colvin, Darell D Bigner, M. E Dolan, Anthony Pegg, Robert Moschel, Jennifer Quinn
Phase I trial of temodar plus O6-benzylguanine in the treatment of patients with recurrent or progressive cerebral anaplastic gliomas

ASCO Proceedings, 2002 Annual Meeting, Abstract No. 311 


Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
J Clin Oncol 1998 Dec;16(12):3851-7 

Gander M, Leyvraz S, Decosterd L, Bonfanti M, Marzolini C, Shen F, Lienard D, Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M, D'Incalci M.
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Ann Oncol 1999 Jul;10(7):831-8
  Abstract |   Reprint |   Related articles

Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study
J Clin Oncol 1998 Oct;16(10):3310-5  

Takao Kanzawa, Hideaki Ito, Yasuko Kondo, Seiji Kondo
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
Proceedings of the AACR, Volume 45, March 2004, Abstract Number: 579. 

Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo S, Kondo S
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide
Br J Cancer. 2003 Sep 1;89(5):922-929

Satoshi Nakasu, Tadateru Fukami, Kazumi Baba, Masayuki Matsuda
Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas
Journal of Neuro-Oncology, 70(3): 333-340, December 2004. (Abstract+)

Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, Sanchez-Cespedes M, Garcia-Villanueva M, Arribas L, Esteller M
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas
Clin Cancer Res. 2004 Aug 1;10(15):4933-8. 

Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T
A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma
J Neurooncol. 2004 Feb;66(3):365-75. (Abstract+)

J. A. Quinn, J. Weingart, H. Brem, J. Rich, D. Reardon, J. Sampson, A. Friedman, H. S. Friedman, O. M. Colvin, E. Dolan
Phase I trial of temozolomide plus O6-benzylguanine in the treatment of patients with recurrent or progressive cerebral anaplastic gliomas
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 411 

Jennifer A. Quinn, M. Eileen Dolan, Anthony E. Pegg, Robert C. Moschel, James Pluda, Roger E. McLendon, James Provenzale, William Petros, Sandra Tourt-Uhlig, Jeremy N. Rich, Sridharan Gururangan, Mary L. Affronti, Waynette Buchanan, O. Michael Colvin, Elizabeth S. Stewart, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman
Phase II Trial of BCNU Plus O6-Benzylguanine for Patients with Recurrent or Progressive Malignant Glioma
ASCO Proceedings, 2001 Annual Meeting, Abstract No.251
 

S. N. Raval, B. Gu, J. J. Raizer, M. K. Rosenblum, D. Banerjee, J. R. Bertino, L. M. DeAngelis
Methylation of MGMT promotor, the DNA repair gene as an independent prognostic factor for malignant glioma
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No. 452
 

Mark Rosenblum, J Weingart, Eileen Dolan, S Tatter, K Judy, J Olson, E Bohan, J Fisher
Phase I study of Gliadel combined with a continuous intravenous infusion of O6-benzylguanine in patients with recurrent malignant glioma
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract No. 314 

Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W
Mechanisms of chemoresistance to alkylating agents in malignant glioma
Clin Cancer Res. 2008 May 15;14(10):2900-8
 Abstract

S. Clifford Schold Jr., Demetrius M. Kokkinakis, Susan M. Chang, Mitchel S. Berger, Kenneth R. Hess, David Schiff, H. Ian Robins, Minesh P. Mehta, Karen L. Fink, R.L. Davis, and Michael D. Prados
O6-Benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas
Neuro-Oncology, January 2004, Volume 6 Number 1, Pages 28 -- 32 

Antonio Silvani,  Marica Eoli, Andrea Salmaggi, Elena Lamperti, Elio Maccagnano, Giovanni Broggi, Amerigo Boiardi
Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients
Journal of Neuro-Oncology, 66 (1-2): 203-208, January 2004 

Slancar M., Wheeler H., Cook R., Levi J., Bell D., Beith J.
Increased pulmonary toxicity with scheduling procarbazine prior to BCNU in patients with high-grade gliomas

ASCO Proceedings, 1997 Annual Meeting, Abstract No. 1459 

Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard I, Delorenzi M, Flamion B, Diguiseppi J, Bierau K, Hegi ME
Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma
J Mol Diagn. 2008 Jul;10(4):332-337. Epub 2008 Jun 13
 Abstract


Gliomas (High-Grade)


Pan Q, Yang XJ, Wang HM, Dong XT, Wang W, Li Y, Li JM.
Chemoresistance to Temozolomide in Human Glioma Cell Line U251 is Associated with Increased Activity of O (6)-methylguanine-DNA Methyltransferase and Can be Overcome by Metronomic Temozolomide Regimen.
Cell Biochem Biophys. 2011 Sep 4;. [Epub ahead of print]
  Abstract |   Related articles°

Rahman R, Smith S, Rahman C, Grundy R.
Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma
J Oncol. 2010;2010:251231. Published online 2010 April 11
  Abstract |   Full Text |   Reprint

Suri V, Jha P, Sharma MC, Sarkar C.
O 6 -methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: A review of current status
Neurol India, 2011 March-April, Volume 59 Issue 2, 59:229-235
  Abstract |   Full text

Tanaka S, Akimoto J, Kobayashi I, Oka H, Ujiie H
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction
Oncol Rep. 2008 Jul;20(1):165-71
 Abstract

Yang SH, Kim YH, Kim JW, Park CK, Park SH, Jung HW
Methylation Status of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene Promoter in World Health Organization Grade III Gliomas
J Korean Neurosurg Soc. 2009 Oct;46(4):385-8
  Abstract |   Full Text |   Reprint


Malignant Lymphoma


B. Evans, J. Quinn, D. Reardon, J. Rich, S. Gururangan, A. Friedman, R. McLendon, S. Tourt-Uhlig, V. Stafford-Fox, H. S. Friedman
Phase II treatment of adults with newly diagnosed, progressive or recurrent primary central nervous system lymphoma with temozolomide
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 438 

Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M, Herrlinger U
Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status
J Neurooncol. 2010 May;97(3):389-92. Epub 2009 Oct 20
  Abstract |   Full Text |   Reprint


Medulloblastoma


Demetrius M. Kokkinakis, Robert C. Moschel, Anthony E. Pegg and S. Clifford Schold
Eradication of Human Medulloblastoma Tumor Xenografts with a Combination of O6-Benzyl-2'-deoxyguanosine and 1,3-Bis(2-chloroethyl)-1-nitrosourea
Clinical Cancer Research Vol. 5, 3676-3681, November 1, 1999. (PDF Full Text)


Meningioma


de Robles P, McIntyre J, Kalra S, Roldán G, Cairncross G, Forsyth P, Magliocco T, Hamilton M, Easaw J
Methylation status of MGMT gene promoter in meningiomas
Cancer Genet Cytogenet. 2008 Nov;187(1):25-7
  Abstract


Metastatic Tumors


Lucio Tentori, Carlo Leonetti, Marco Scarsella, Weizheng Xu, David C. Calvin, Lisa Morgan, Zhaocheng Tang, Krystyna M. Wozniak, Christina Alemu, Randall Hoover, Rena G. Lapidus, Gabriella Zupi, Jie Zhang, Grazia Graziani
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of temozolomide against melanoma growing at the CNS site
Proceedings of the AACR, Volume 45, March 2004, Abstract Number: 2007. 


Non-CNS Tumors


D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J
Involvement of the mismatch repair system in temozolomide-induced apoptosis
Mol Pharmacol 1998 Aug;54(2):334-41 


Pediatric Patients


Michael S. Bobola, Richard Ellenbogen, Ryan Goff, John Silber
Ablation of O6-methylguanine-DNA methyltransferase with O6-benzylguanine reduces the resistance of pediatric primary brain tumor cell lines to temozolomide and BCNU
Proceedings of the AACR, Volume 45, March 2004, Abstract Number: 2143. 

Broniscer A, Gururangan S, Macdonald TJ, Goldman S, Packer RJ, Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY, Kun LE, Boyett JM, Gajjar A; for the Pediatric Brain Tumor Consortium.
Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report
Clin Cancer Res. 2007 Nov 15;13(22):6712-6718
Abstract

Lee JY, Park CK, Park SH, Wang KC, Cho BK, Kim SK.
MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.
Childs Nerv Syst. 2011 Jul 26. [Epub ahead of print]
  Abstract |   Related articles

Sardi I, Cetica V, Massimino M, Buccoliero AM, Giunti L, Genitori L, Aricò M
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors
Oncol Rep. 2009 Oct;22(4):773-9
  Abstract

bottom


This website is certified by Health On the Net Foundation. Click to verify. HOME ARCHIVES OF NEURO-ONCOLOGY CURRENT NEURO-ONCOLOGY NEWS CLINICAL NEURO-ONCOLOGY LIBRARY
DATABASE: Classification | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Management | Prognosis | Psychosocial Aspects | Stem Cells | Treatment
SERVICES
: About BrainLife | Children's Corner | E-mail Alerts | Journals | Links |
Motto, Dedication, etc. | Patients & Caregivers | Privacy Policy | Search | SiteMap bottom
This site complies with the HONcode standard for trustworthy health information: verify here